Skip to content

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو | English

facebook
twitter
envelope

Menu

About Us
Therapeutic Goods
Safety Info
News & Updates
Publications
E-Services
Medicine Availability
Support

Home > Safety Info > Safety Communication > Safety Alerts > Potential Risk of Tumour Lysis Syndrome with Sorafenib

Potential Risk of Tumour Lysis Syndrome with Sorafenib

Abdul Qadir Safety Alerts April 25, 2025July 18, 2025

57-Potential-Risk-of-Tumour-Lysis-Syndrome-with-Sorafenib Download

Share this:

Twitter
Facebook

← Safety Alert of Risk of persistent corneal injury and significant visual impairment with Chlorhexidine (cutaneous use)
Decisions of 85th Meeting of the Medical Device Board →

Product Recalls
Safety Communication
Safety Reporting

Quick Navigation

Quick Navigation

Archives

Archives

Drug Regulatory Authority of Pakistan

Islamabad | Karachi | Lahore | Peshawar | Quetta
Phone: 0800-03727 (Mon to Fri 08:30AM to 04:30PM)
Website: www.dra.gov.pk

Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan

Contact Us
Report a Problem